Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Paragon Genomics has commercialized its proprietary CleanPlex® amplicon-based target enrichment technologies for DNA and RNA next-generation sequencing. These products are widely adopted by research and clinical labs globally for applications including precision oncology, infectious diseases, inherited diseases, public health surveillance, single-cell analysis, and molecular breeding. The company’s technologies enable rapid custom panel design with high sensitivity and specificity but do not themselves generate clinical trial results since they are research tools/platforms rather than therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Paragon Genomics.